Welcome to our dedicated page for PROSHARES TR news (Ticker: QB), a resource for investors and traders seeking the latest updates and insights on PROSHARES TR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PROSHARES TR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PROSHARES TR's position in the market.
Guided Therapeutics (OTC:QB GTHP) has completed patient enrollment in its FDA clinical trial for the LuViva Advanced Cervical Scan, a non-invasive cervical cancer detection device. The study successfully enrolled approximately 430 patients across four clinical sites, meeting minimum quota requirements.
The company is now transitioning to data analysis, which includes external review of biopsy samples, case report form evaluation, and statistical analysis. No adverse events were reported during the trial, supporting LuViva's FDA designation as a non-significant risk device. The clinical report is expected to be filed with the FDA later in 2025.
Guided Therapeutics (OTC:QB GTHP), manufacturer of the LuViva Advanced Cervical Scan, has initiated its first shipment to Hangzhou Dongye Medical Technology Company (HDMT) on June 27, 2025. This shipment will generate $117,462 in sales revenue for Q2 2025.
The company has also manufactured and tested three devices from a separate $700,000 purchase order with HDMT, triggering a $70,000 payment expected in July 2025. HDMT serves as the exclusive gynecology products provider for 42 hospitals in Hangzhou City, conducting approximately two million cervical cancer screenings annually.
ProShares has launched three innovative Dynamic Buffer ETFs tracking major U.S. indices: S&P 500 (FB), Nasdaq-100 (QB), and Russell 2000 (RB). These groundbreaking ETFs feature a patent-pending methodology that allows investors to participate in market gains up to a cap while providing dynamic downside protection of 1-5% on daily losses.
The unique feature is their automatic adjustment mechanism - as market volatility increases, both the buffer protection and upside cap increase proportionally. Unlike conventional buffer ETFs that require specific holding periods, these new products offer more flexible protection without timing restrictions. The launch comes as Buffer ETFs have accumulated $65 billion in assets under management.
Manhattan Scientifics Inc. (OTC: QB) holds over 50 million shares of Imagion Biosystems (IBX.AX), focused on developing advanced non-radioactive cancer imaging technology. A televised interview with Imagion's CEO, Bob Proulx, is highlighted, discussing their innovative diagnostic solutions aimed at early cancer detection. The press release emphasizes the partnership and technology transfer efforts with Los Alamos and Sandia National Laboratories in New Mexico. The company warns that investments are high risk, with future results uncertain, stressing forward-looking statements are not guarantees of performance.
FAQ
What is the current stock price of PROSHARES TR (QB)?
